Compare NTST & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | MLTX |
|---|---|---|
| Founded | 2019 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2020 | 2020 |
| Metric | NTST | MLTX |
|---|---|---|
| Price | $17.39 | $11.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 15 |
| Target Price | $22.92 | ★ $28.54 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.09% | N/A |
| EPS Growth | ★ 150.00 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $195,006,000.00 | N/A |
| Revenue This Year | $29.01 | N/A |
| Revenue Next Year | $18.49 | N/A |
| P/E Ratio | $149.63 | ★ N/A |
| Revenue Growth | ★ 19.79 | N/A |
| 52 Week Low | $17.02 | $7.50 |
| 52 Week High | $22.47 | $23.29 |
| Indicator | NTST | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 18.87 | 31.71 |
| Support Level | $17.10 | $11.06 |
| Resistance Level | $17.88 | $19.24 |
| Average True Range (ATR) | 0.43 | 0.61 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 0.80 | 14.63 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.